Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.
Pulmonary involvement including interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic sclerosis (scleroderma; SSc). This article reviews the current evidence based medicine regarding available therapies for SSc-ILD ; discusses the lessons learned from recent SSc-ILD randomized controlled trials (RCTs); and proposes outcome measures and recommendations for design of future RCTs for SSc-ILD.
Khanna
Dinesh
D
Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Seibold
James R
JR
Wells
Athol
A
Distler
Oliver
O
Allanore
Yannick
Y
Denton
Chris
C
Furst
Daniel E
DE